Top Biotech Stocks To Invest In 2016

Top Biotech Stocks To Invest In 2016: Sanofi(SNY)

sanofi-aventis engages in the discovery, development, and distribution of therapeutic solutions to improve the lives of everyone. The company offers a range of healthcare assets, including a broad-based product portfolio in prescription drugs, OTC/OTX, generics, vaccines, and animal health. It has a strategic alliance with Regulus Therapeutics Inc. to discover, develop, and commercialize micro-RNA therapeutics, initially in fibrosis. The company was founded in 1970 and is headquartered in Paris, France.

Advisors' Opinion:

• [By Jonas Elmerraji]

  French pharmaceutical firm Sanofi (SNY) is another stock that's been in a downtrending channel since the start of the summer. Even though health care stocks (especially biotechs) have posted standout numbers in 2013, Sanofi is only 6.8% higher than it was at the beginning of the year. Sure, that might be a decent return on a typical year, but when equity indices are seeing gains in the low 20% range, Sanofi's performance is horrific.

  Just like Coke, Sanofi is testing trendline resistance this week. That means that it makes sense to sell the bounce lower off of that price ceiling. Selling the bounce makes sense for two key reasons: First, it's the place where the risk is the least (because you'll know you're wrong soonest if SNY moves through resistance), and it's also the spot with the most downside to trendline support for short sellers.

  Buyers should stay away from SNY in October. There are plenty of better names in the healthcare space right now. Focus on relative strength winners instead.

• [By Keith Speights]

  Eylea isn't the only feather in Regeneron's cap, though. The company partnered with Sanofi (NYSE: SNY  ) on colorectal cancer drug Zaltrap, which gained FDA approval last August. While sales were sluggish initially, a steep price cut for the drug to make it more competitive should help.

• [B! y Johanna Bennett]

  Regeneron (REGN) climbed 3.2% after its partner Sanofi (SNY) said an experimental asthma drug produced good results in clinical trials. Sanofi climbed 1.9%.

• [By Daniel Kline]

  While Netflix has had success making its shows feel like events, other networks have struggled to gain attention for theirs. Amazon, for example, has gotten a little notice for its Alpha House series thanks to star John Goodman and creator Garry Trudeau (of Doonesbury fame), but its other comedy series,Betas, has mostly gone unnoticed. Yahoo! is also entering a crowded field that's about to get even more crowded as Microsoft (NASDAQ: MSFT  ) has announced plans for at least six original series for its Xbox One platform and Sony (NYSE: SNY  ) is launching at least one show on its PlayStation Network, Bloomberg reported.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-biotech-stocks-to-invest-in-2016.html